ABBOTT VASCULAR INC.
Manufacturer adverse-event records for ABBOTT VASCULAR INC. come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2005–2026 · heavy-book · elevated Death-code · injury-heavy
Injury-mix signature
ABBOTT VASCULAR INC. leans injury-heavy in event_type mix
Injury-coded event_type share is 72.6% (injury-heavy tercile) beside 0.76% Death-coded (elevated). Volume band: heavy.
What the Injury-mix reading shows for ABBOTT VASCULAR INC.
The standout signal for ABBOTT VASCULAR INC. is Injury-mix: 72.6% Injury-coded (injury-heavy) beside 0.76% Death-coded, on a heavy-book footprint.
As a heavy-book manufacturer, portfolio size and reporting obligations inflate absolute counts - pair ABBOTT VASCULAR INC. with device-family pages before treating company totals as a safety verdict. Event_type Death and Injury are one code per report; Patient Outcomes below use a separate FDA population.
Reports span 20 device types, led in this extract by Injury at 17,881 (72.6% of event_type total). Peak single-year volume reaches 12,030 reports across 22 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (20)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.